PainChek Ltd ( (AU:PCK) ) has shared an update.
PainChek Ltd reported a 21% increase in total revenue and other income for the half-year ending December 31, 2024, compared to the previous year, driven by a 27% rise in revenue from continuing operations and a 14% increase in R&D grants. Despite this growth, the company recorded a net loss of $3.16 million, a slight improvement from the previous period. The financial report highlights a concern regarding the company’s going concern status, as noted by the independent auditor, which may impact its future operations and stakeholder confidence.
More about PainChek Ltd
PainChek Ltd operates in the healthcare industry, focusing on the development and commercialization of pain assessment technologies. The company primarily offers digital tools designed to assess and manage pain, particularly in patients who are unable to communicate effectively.
YTD Price Performance: 10.0%
Average Trading Volume: 968,083
Technical Sentiment Consensus Rating: Strong Buy
Current Market Cap: A$59.66M
Find detailed analytics on PCK stock on TipRanks’ Stock Analysis page.